# 3billion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/3billion

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.3billion.io
- Total disclosed funding: $18M
- Latest round: Series C (Dec 17, 2020)
- Investors on record: 13

## About

Based in South Korea, 3billion is a genetic testing company focusing on rare diseases, providing innovative solutions for diagnosing genetic variations through advanced sequencing technologies.3billion was founded in 2016 in Seoul, South Korea, specializing in genetic testing for rare diseases. The company has completed 6 deals, with its most recent deal occurring on November 14, 2024, through a Pre-IPO round, raising KRW 13,150 million from investors including Korea Development Bank, Magna Investment, and SK Securities, which contributed to its current valuation of KRW 150,000 million. The CEO, Changwon Keum, leads the company in its strategic operations.3billion specializes in genetic testing for rare diseases, offering products like 3B-GENOME, 3B-EXOME, 3B-VARIANT, and 3B-INTERPRETER that enable comprehensive genetic analyses via whole genome and exome sequencing. These products utilize buccal swabs for sample collection, thereby simplifying the diagnostic process for healthcare providers. The company serves a diverse client base across over 70 countries, particularly focusing on North America, Europe, and parts of Asia where genetic testing access is increasing.In 2024, 3billion reported a revenue of KRW 4,234,859.10, with an EBITDA of KRW -4,207,841.40. The company generates revenue through B2B transactions with healthcare providers and institutions, often through one-time orders or contractual agreements for genetic tests. Products such as 3B-GENOME and 3B-EXOME play a central role in their revenue generation, complemented by partnerships with pharmaceutical firms for collaborative research and development.3billion plans to leverage its recent IPO, raising KRW 14.4 billion on November 14, 2024, by selling 3.2 million shares at KRW 4,500 each, to enhance its research capabilities and expand its market reach. The company aims to introduce new products designed to improve the accuracy and efficiency of genetic testing. Additionally, it is targeting expansion into new geographic markets, including further penetration into Europe and Asia, aiming for significant market presence by 2025.

## Funding rounds

- Series C, Dec 17, 2020, $5.9M — Korea Investment & Securities, Yuanta Investment, Kakao Investment, Magna Investment, The Wells Investment, JW Asset, A Ventures
- Series B, Oct 1, 2019, $9.6M — KDB Bank, Yuanta Investment, Shinhan Capital, Daekyo Investment, Magna Investment, The Wells Investment, Nvestor, D3 Jubilee Partners, JW Asset, A Ventures
- Series A, Jun 29, 2018, $2.7M — KDB Bank, JW Asset Management, The Wells Investment

## Investors

- KDB Bank — Series A, Series B
- JW Asset Management (https://capitalatlas.ai/funds/jw-asset-management) — Series A
- The Wells Investment (https://capitalatlas.ai/funds/the-wells-investment) — Series A, Series B, Series C
- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series B, Series C
- Shinhan Capital (https://capitalatlas.ai/funds/shinhan-capital) — Series B
- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series B
- Magna Investment (https://capitalatlas.ai/funds/magna-investment) — Series B, Series C
- Nvestor (https://capitalatlas.ai/funds/nvestor) — Series B
- D3 Jubilee Partners (https://capitalatlas.ai/funds/d3-jubilee-partners) — Series B
- JW Asset — Series B, Series C
- A Ventures — Series B, Series C
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series C
- Kakao Investment (https://capitalatlas.ai/funds/kakao-investment) — Series C